Quantitative approaches to drug development
We provide consultancy services to help our clients reduce uncertainty in research and regulatory questions, increasing confidence in the development of new medicines that can improve patients’ lives. Science and Services
About
Pharmetheus reduces uncertainty in all phases of drug development.
News
Jurgen Langenhorst shares his path towards becoming a senior consultant and team leader at Pharmetheus, and why clinical data is more than just numbers to him.
-Bringing Lourdes onboard is an important step in putting further emphasis on developing our QSP capacity. Her experience will be of essence in meeting the growing demand for QSP services from our clients, says Marylore Chenel, Chief Research Officer and the recruiting manager. The recruitment of a senior scientist within QSP, like Lourdes Cucurull-Sanchez, will allow the company to split…
Current treatments in infantile colic are insufficient, with inadequate efficacy or intolerableside-effects. Nepadutant, a tachykinin NK₂ receptor antagonist, was considered a promisingcandidate through its mechanism of action and for its potential to be dosed orally in infants. In a new publication the pharmacokinetics and exposure–response (durationof crying and fussing) following treatment with nepadutant were described in infants (4-20weeks) with colic. Read more about this…
How we work
Traceability, accountability, and independent quality control are of utmost importance to us, and embedded in our way of working.
Publications
Explore our scientific publications.
Explore our web
Model Informed Drug Development
A quantitative framework to support and inform development program strategies and decisions.
“Sharing with colleagues is why I love working here”
Sophie Peigné supports clients with expert and strategic advice in pharmacometrics as well as hands-on modeling analyses for compounds in all development phases.
History of Pharmetheus
Our journey is an exciting one. We began as a start-up that spinned off from Uppsala University. Today, we have grown into a global medium-sized company, adding value to drug development each day.